Feature
FDA Trends for Reusable Medical Device Reprocessing Validations
Feb 01, 2012
As technology advances, so does the complexity of medical devices. Increased design complexity intensifies the difficulty A medical device going through...
Future Risks: How Biomedical Companies Navigated Turbulent Economic Times
Jan 30, 2012
  Future Risks and Dangers After five relatively good years, the medical device industry faces a more challenging future, with significant risks to...
Key Challenges: How Biomedical Companies Navigated Turbulent Economic Times
Jan 30, 2012
  Key Challenges to Continued Success   Lack of Focus. As a result of the ongoing acquisitions and continuing investment in R&D, many firms...
R&D and Investment: How Biomedical Companies Navigated Turbulent Economic Times
Jan 30, 2012
  Investment in R&D and New Products Over the past few years the way the medical devices industry assesses innovation and new technology has changed...
How Biomedical Companies Navigated Turbulent Economic Times
Jan 30, 2012
While most giant corporations crashed during the worst economic climate since the Great Depression, the biomedical devices industry grew, invested, and...
Approach and Methodology: How Biomedical Companies Successfully Navigated Turbulent Economic Times
Jan 30, 2012
Approach and Methodology      To conduct this study, we sought out top firms in the medical device and technology sector with a primary...
What You Should Know about Patent Reform: The Post-Grant Review Process
Jan 22, 2012
MD+DI: Could you explain the post-grant patent review process?   David Dykeman is a patent attorney and co-chair of the IP department at...
MX: Device Patents: Think Globally, File Locally
Jan 19, 2012
The United States entered a new phase of patent harmonization when the America Invents Act (AIA) was signed into law in September 2011. As a result of AIA...
MX: How To Develop A Strong Patent Portfolio
Jan 19, 2012
In the competitive medtech IP environment, a strong patent position may represent the lifeblood of a company. To attain that position, a medical device company...
The MX Q&A: David Parkinson, Nodality
Jan 19, 2012
During his years leading drug-development efforts at major biomed companies, David Parkinson says his frustration mounted as the industry couldn’t quite...